A plant-based cancer vaccine that kick-starts the immune system and can be tailored to target specific tumor types shows promise, according to U.S. researchers who tested the vaccine on 16 people with incurable follicular B-cell lymphoma.
More than 70 percent of the patients developed an immune response and none of them showed any significant side effects, Agence France-Presse reported. The study appears in the journal Proceedings of the National Academy of Sciences.
